These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8117716)

  • 21. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
    Hervio L; Chapman MJ; Thillet J; Loyau S; Anglés-Cano E
    Blood; 1993 Jul; 82(2):392-7. PubMed ID: 8329699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphic forms of Lp(a) with different structural and functional properties: cold-induced self-association and binding to fibrin and lysine-Sepharose.
    Fless GM; Snyder ML
    Chem Phys Lipids; 1994 Jan; 67-68():69-79. PubMed ID: 8187246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.
    Nesheim M; Fredenburgh JC; Larsen GR
    J Biol Chem; 1990 Dec; 265(35):21541-8. PubMed ID: 2123871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study.
    Rouy D; Laplaud PM; Saboureau M; Anglés-Cano E
    Arterioscler Thromb; 1992 Feb; 12(2):146-54. PubMed ID: 1531929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein(a), fibrin binding, and plasminogen activation.
    Loscalzo J; Weinfeld M; Fless GM; Scanu AM
    Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does lipoprotein(a) (Lp(a)) complete with plasminogen in human atherosclerotic lesions and thrombi?
    Smith EB; Crosbie L
    Atherosclerosis; 1991 Aug; 89(2-3):127-36. PubMed ID: 1838924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein(a), plasmin modulation, and atherogenesis.
    Harpel PC; Hermann A; Zhang X; Ostfeld I; Borth W
    Thromb Haemost; 1995 Jul; 74(1):382-6. PubMed ID: 8578490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W; Koschinsky ML
    Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The inter-relation of fibrin, lipoprotein(a) and plasminogen in human atherosclerotic lesions.
    Smith EB; Crosbie L; Cochran S
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):495-8. PubMed ID: 2151935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)).
    Smith EB; Cochran S
    Atherosclerosis; 1990 Oct; 84(2-3):173-81. PubMed ID: 2149268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the lysine binding functions of lipoprotein(a) and plasminogen.
    Hoover-Plow JL; Miles LA; Fless GM; Scanu AM; Plow EF
    Biochemistry; 1993 Dec; 32(49):13681-7. PubMed ID: 8257702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
    Rouy D; Anglés-Cano E
    Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formation and elimination of soluble fibrin and D-dimer in the bloodstream.
    Udovenko A; Makogonenko Y; Korolova D; Druzhyna N; Chernyshenko V; Komisarenko S
    Croat Med J; 2023 Dec; 64(6):421-429. PubMed ID: 38168523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE; Smith CJ
    Arch Biochem Biophys; 1993 Nov; 307(1):138-45. PubMed ID: 8239651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin.
    Angles-Cano E; Rouy D; Lijnen HR
    Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lipoprotein(a) and LDL on plasminogen binding to extracellular matrix and on matrix-dependent plasminogen activation by tissue plasminogen activator.
    Pekelharing HL; Kleinveld HA; Duif PF; Bouma BN; van Rijn HJ
    Thromb Haemost; 1996 Mar; 75(3):497-502. PubMed ID: 8701415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases.
    de la Peña-Díaz A; Cardoso-Saldaña G; Zamora-González J; Barinagarrementeria F; Izaguirre R; Loyau S; Anglés-Cano E
    Eur J Clin Invest; 2003 Feb; 33(2):99-105. PubMed ID: 12588282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
    Sangrar W; Gabel BR; Boffa MB; Walker JB; Hancock MA; Marcovina SM; Horrevoets AJ; Nesheim ME; Koschinsky ML
    Biochemistry; 1997 Aug; 36(34):10353-63. PubMed ID: 9265615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
    Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
    Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.